

29 February 2008

Level 14, Cigna House,
40 Mercer Street, PO Box 10-254,
Wellington 6143, New Zealand

Phone 64-4-460-4990

Fax 64-4-460-4995

www.pharmac.govt.nz

PHARMAC consultation

Proposal to list new brands of bromocriptine and clomipramine

Proposal summary

PHARMAC is proposing to list new brands of the antiparkinson agent bromocriptine mesylate and the antidepressant clomipramine hydrochloride in the Pharmaceutical Schedule.

These listings are proposed because the existing brands of these medicines are being discontinued by the current suppliers. PHARMAC has actively sought alternatives to ensure that patients continue to have access to these medicines.

Feedback sought

We welcome your feedback on this proposal. To provide feedback please submit it in writing by **5pm, Friday, 14 March 2008** to:

Geraldine MacGibbon
Therapeutic Group Manager
PHARMAC
PO Box 10-254
Wellington 6143

Email: geraldine.macgibbon@pharmac.govt.nz

Fax: (04) 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) before making a decision on this proposal.

Details of the proposal

We have entered into a provisional agreement with Apotex NZ Limited:

- Bromocriptine mesylate 2.5 mg and 5 mg (Apo-Bromocriptine) would be listed in Section B of the Pharmaceutical Schedule fully subsidised at \$32.08 per 100 tablets and \$60.43 per 100 capsules, respectively (ex-manufacturer, excluding GST). The listing would be timed to coincide with discontinuation of the current brand of bromocriptine mesylate 2.5 mg and 10 mg (Alpha-Bromocriptine) in about a year. The listing of Apo-Bromocriptine 5 mg would be subject to Medsafe registration.
- Clomipramine hydrochloride 10 mg and 25 mg (Apo-Clomipramine) would be listed in Section B of the Pharmaceutical Schedule fully subsidised at \$12.60 per 100 tablets and \$43.42 per 500 tablets, respectively (ex-manufacturer, excluding GST). The listing would be timed to coincide with discontinuation of the current brand of clomipramine hydrochloride 10 mg and 25 mg (Clopress) in the middle of 2009. The listing of Apo-Clomipramine would be subject to Medsafe registration.
- Apo-Bromocriptine and Apo-Clomipramine would have protection from subsidy reduction and delisting until 1 July 2012.